Revance Therapeutics Inc (NASDAQ:RVNC) price on current trading day, rose 10.86% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $3.62.
A look at the stock’s price movement, the level at last check in today’s session was $3.27, moving within a range at $3.6 and $3.7. The beta value (5-Year monthly) was 0.953. Turning to its 52-week performance, $7.56 and $2.30 were the 52-week high and 52-week low respectively. Overall, RVNC moved 17.31% over the past month.
Revance Therapeutics Inc’s market cap currently stands at around $378.41 million, with investors looking forward to this quarter’s earnings report slated for in February.
Analysts have a consensus estimate of 77.96M for the company’s revenue for the quarter, with a low and high estimate of 64M and 87.49M respectively. The average forecast suggests up to a 11.69% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 263.56M, representing a 12.61% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that RVNC is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 7 recommend RVNC as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
RVNC’s current price about 13.20% and 0.24% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 60.17, while 7-day volatility ratio is 2.45% and 1.66% in the 30-day chart. Further, Revance Therapeutics Inc (RVNC) has a beta value of 0.89, and an average true range (ATR) of 0.15. Analysts have given the company’s stock an average 52-week price target of $6.66, forecast between a low of $6.66 and high of $6.66. Looking at the price targets, the low is -83.98% off recent price level in today’s trading while to achieve the yearly target high, it has to move -83.98%. Nonetheless, investors will most likely welcome a -83.98% jump to $6.66 which is the analysts’ median price.
If we refocus on Revance Therapeutics Inc (NASDAQ:RVNC), historical trading data shows that trading volumes averaged 3.11 over the past 10 days and 2.81 million over the past 3 months. The company’s latest data on shares outstanding shows there are 104.90 million shares.
The 8.76% of Revance Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 85.60% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 8.34 million on 2024-12-31, giving us a short ratio of 2.52. The data shows that as of 2024-12-31 short interest in Revance Therapeutics Inc (RVNC) stood at 917.0 of shares outstanding, with shares short falling to 12.7 million registered in 2024-11-29. Current price change has pushed the stock 19.24% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the RVNC stock continues to rise going into the next quarter.
